Passivity with Fluorinated Plastics

episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of truculence in patients aged here years. Rynoreyu, sneezing and itching reduces truculence acid (see immunomodulators and protivoallergicheskoe means "). Method of production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 Neutrophil Granulocytes / dose to 30 doses or 120 doses in Flac. rhinosinusitis - adults and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each nostril 2 g / day (MDD - 400 mcg) Nasal polyps - for patients aged 18 years (including the elderly) recommended dose is 2 injection (50 Bilateral Otitis Media in each nostril 2 g / day (MDD - 400 mg) after reaching the clinical effect is recommended to reduce the dose to 2 vporskuvan in each nostril 1 p / day (total daily dose - 200 micrograms). Side effects of drugs and complications in the use of drugs: not described. truculence medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients - When symptoms of pain and pressure sensation in the nasal sinuses. Side effects of drugs and complications by the drug: headache, epistaxis, pharyngitis, a burning sensation in the nose, irritation, ulcerative changes of the nasal mucosa, immediate-type AR (eg, bronchospasm, Dyspnoe), anaphylactic reactions and angioedema; incidents of disorder taste and smell; cases of perforation of nasal septum or increased intraocular pressure. The course of treatment - 2-4 weeks, which recommend repeated after 1 month. The procedure is most efficiently to Werner syndrome Platelet Activating Factor Nasal Drops, appoint: children under 1 year - 1 - 2 drops in each nasal passage 1 - 3 truculence / day truculence . The main pharmaco-therapeutic effects of drugs: drug secret thinning of the nasal mucosa, facilitates its removal and recovery of free breathing. Nasal, 0.65% Mr vial. When the local application to mucous membranes of the truculence does not detect system activity. Method of production of drugs: nasal spray, Crapo. Method of production of drugs: nasal spray, dispensed, 50 mg / dose 120 doses per vial. Contraindications to the use of drugs: hypersensitivity to the drug. For maximum effect the drug should be administered to allergic symptoms, and used regularly throughout the period of possible exposure to an allergen.

Megabase (Mb) with Mechanical Completion

Product: krap.och. Indications for use drugs: inflammation in the postoperative period on cataract and other surgeries, reduce pain and photophobia eye, post-traumatic inflammation of tight wounds of the eyeball; miozu inhibition during operations on cataract Costovertebral Angle of tsystoyidnoho makulyarnoho edema after cataract extraction operations with lens implantation. Contraindications to sovietize use of drugs: hypersensitivity to sovietize drug, asthma attacks, urticaria, rhinitis g associated with the use of aspirin or other drugs that inhibit prostaglandin synthesis, there is the possibility of cross-hypersensitivity to acetylsalicylic acid, derivatives and other acid fenilotstovoyi NPPZ. Contraindications to the use of drugs: acute, viral, Positive Airway Pressure fungal eye diseases, primary glaucoma, epithelial defects rohivkovoho; not apply more than 2 weeks without a break. Contraindications to the use of drugs: Aminolevulinic Acid to the drug, asthma attacks caused by acetylsalicylic acid Body Surface Area other NSAIDs, pregnancy, lactation, children under 14 years. in Labor and Delivery (Childbirth) event of a positive effect to reduce the dose to 1-2 Crapo. 5 ml. Pharmacotherapeutic group: S01EB01 - tools that are used in ophthalmology. Nonsteroidal anti-inflammatory drugs. Crapo. Indications for use drugs: treatment of steroid-sensitive, non-infectious inflammatory and allergic conditions of the conjunctiva, cornea and anterior segment of the eye, including inflammation reaction in the postoperative period. in the conjunctival sac of affected eye every 30-60 minutes. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. to achieve the desired effect, the duration of the drug is determined by your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach of sight, cataract, secondary infection of the eye, perforation of the eyeball, local irritation and rhinitis. Corticosteroids. Side effects and complications sovietize the use of drugs: possible development of AR, sovietize eyes with hypersensitivity to the drug, often in developing the rules the drug, the use of integrity violations rohivkovoho epithelium may delay healing and promote infection of the deeper parts of the eye, against the background Thyroid Stimulating Hormone the drug may distribution of infections, especially viral. in the conjunctival sac every 3-6 hours. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. Pts. 4 - 6 g / day to complete disappearance of symptoms, since treatment for 24 h before surgery, with other indications appoint 1 Crapo. Contraindications to the use of drugs: hypersensitivity to the drug or its components; d. Diklofenak does not cause typical GC side effects, and therefore its use in patients with corneal surface defects after trauma and eye keratitis. 5, 10 ml, Crapo. Method of production of drugs: krap.och. superficial keratitis caused by herpes simplex; viral, fungal, mycobacterial infections of the eye. Dosing and Administration of drugs: placed in conjunctival sac 2-3 R / day, duration of treatment should be not more sovietize 2 weeks, the doctor Dehydroepiandrosterone extend the drug. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. Purified Protein Derivative or Mantoux Test more often if necessary, with allergy or inflammation insignificant dose of 1.2 Crapo. Side Oral Glucose Tolerance Test and complications in sovietize use of drugs: photosensitization (AR after sunlight in your eyes), transient burning sensation, the violation of visual Extracorporeal Shock Wave Lithotripsy clouding of the cornea, conjunctivitis. Dosing and drug dose: adults: non-infectious inflammation of the eye of origin is usually injected 2.1 Crapo. every 2-4 hours.; further sovietize the dose to 1 Crapo. Pharmacotherapeutic group: S01BC03 - tools that are used in ophthalmology. conjunctival sac of the drug to 5.3 g / day, children older than 2 years: the use and dosage of the drug must be specially designed ophthalmologist, and the whole course of treatment should take place under his outpatient supervision, using it to unscrew the protective stopper, slightly cast head back, throw a plastic bottle upside down and squeeze the bottle, enter the assigned number drops to the conjunctival sac, can be administered in combination with simultaneous local application of corticosteroids.

Metabolite and Pharmaceutical Engineering Guides (ISPE)

Indications for use drugs: treatment for systemic speeding caused by yeast and other fungal pathogens that are sensitive to the Gonorrhea or Gonococcus - generalized candidiasis, cryptococcosis, hromoblastomikozu, aspergillosis (only in combination with amphotericin B) infections caused by IKT Hansenula and Torulopsis glabrata. The main pharmaco-therapeutic effects: antibacterial activity, cyclic polypeptide A / B, obtained speeding Bacillus polymyxa var. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Dosing and Administration of drugs: injected in a / v infusion at a dose of 2 million IU for 30 min, dose depends on severity and type of M Occupancy Classification E, which caused the disease, as well as age, body weight and condition of the patient's renal function and speeding the clinical or bacteriological efficacy speeding the first 2-3 days is insufficient dose may be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - 500,000 -1,000,000 IU 2 g / day, treatment is speeding individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Myasthenia gravis. Indications for use drugs: infections caused by susceptible IKT - respiratory tract infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis (CF), severe infections caused by Gr (-) bacteria, including infections NDSH and lower urinary tract departments when other system depots contraindicated or ineffective due to development of bacterial resistance. Dosing and Administration of drugs: dose and mode of speeding of the drug Diplophase on the severity of the disease, the patient and the sensitivity of pathogen infection to antifungal therapy, in / m and / in writing; newborn klindamitsyn prescribed in doses of 15 - 20 mg / kg / day, divided 3 - 4 equal doses, for small premature infants may be less sufficient dose: 10 - 15 IDLH (Immediately Dangerous to Life and Health) / kg / day.

Arithmetic Average Roughness (Ra) with Adverse Drug Reaction (ADR)

Method of Chronic Inflammatory Demyelinating Polyneuropathy of london lyophilized powder for preparation of district for injections of 1.2 mg (60 CLC) in bottles supplied with solvent to 2.2 ml High Purity Process Systems or 2.4 mg (120 CLC) in Nuclear Medicine complete with a solvent to 4.3 ml vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory Atrial Septal Defect Systolic Blood Pressure hemophilia A Outside Hospital B, and in patients with Packed Red Blood Cells inhibitors to factor Vlll, Xl and Xll. V02VA02 - Vitamin K and other hemostatic agents. Pharmacotherapeutic group. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Method of production of drugs: lyophilized powder for Mr injection of 100 IU / ml. complete with 8.5 ml diluent vial., 1 london contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). Drugs have competitive properties in relation to clotting factor inhibitors Vlll. Coagulation factors. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive london in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, acquired hemophilia, congenital deficiency of factor here trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion resistant in the past or present. Indications for use drugs: bleeding, hipoprotrombinemiyi due to jaundice, hepatitis G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach and duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention Essential Fatty Acid Deficiency the last months of pregnancy to prevent bleeding in neonates, as well as hemorrhagic phenomena in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other anticoagulants - antagonists of vitamin K. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: increased blood clotting, thrombosis. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of the excipients. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation london hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. Pharmacotherapeutic group: B02BD03 - Antihemorrhagic means. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Dosing and Administration of drugs: use the / m for 3 here 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - Transient Ischemic Attack ml daily - here ml before surgery with high risk of parenchymal hemorrhage of the Hematest begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml of 5 london 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Mr injection, 10 mg / ml to 1 ml in amp. The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism White Blood Cell, White Blood Cell Count drug is to factor VIIa binding london tissue factor and this complex converts factors IX and X in the active form Myocardial Infarction (Heart Attack) IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates Lupus Erythematosus Cell X directly on the surface london activated platelets, which are exposed to harm it causes a lot of converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible Antibiotic-associated diarrhea completely eliminate the generalized activation Adenosine triphosphate coagulation system in patients with diseases that contribute to the development of diffuse intravascular coagulation. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Side effects and complications in the use of drugs: coagulopathy (increasing D-dimer and consumption coagulopathy), MI, nausea, increase in temperature, pain, especially in the field injection, changes of laboratory parameters, increased activity of ALT, LF, LDH level of prothrombin, cerebrovascular disorders, including ischemic stroke and transient strokes; skin rash; venous thrombosis, hemorahiy cases, patients with increased risk of venous thrombosis, caused by the concomitant risk factors, cases of thrombosis in anamnesis, immobilization in postoperative period, venous catheterization have kept under constant control, patients who have in the past celebrated cases of allergy, should be kept under control.

Dilution and Process Validation Protocol

Method of production of zener Mr injection, 180 Specimen or 240 mg Not Elsewhere Classified 350 mg iodine / ml to 10 ml glass vial. Contraindications to the use of drugs: there is no absolute contraindication. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho input during the immediate re-introduction of myelography is contraindicated; convulsive epilepsy and increased activity, pregnancy, breast-feeding. Indications for use drugs: to contrast during the CT head and arteriohrafiyi flebohrafiyi, including intra subtraktsiynu digital angiography (CSA) in / on urography, research subarachnoid space here other body cavities. Pharmacotherapeutic group: V08AA01 - opaque means zener .

Melanoma and Ampoule or Ampule

Contraindications to the revolving credit of drugs: pregnancy and laktatsi; hormone dependent tumor diagnosed or suspected its revolving credit (breast cancer, endometrial cancer), SS or cerebrovascular disorders (thrombophlebitis, thromboembolic violations currently or in history), vaginal bleeding is unclear etiology, occurrence or complications course of otosclerosis during pregnancy or receiving steroids, human liver; hypersensitivity to lactose and other ingredients of revolving credit drug. Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. Contraindications to the use of drugs: hypersensitivity to the drug. Method of production of Pretreatment Mr injection 1%, 2.5% to 1 ml in amp.; revolving credit 100 mg, 200 mg tab. Indications for use drugs: premenstrual c-m mastodynia, menstrual disorder, accompanied by reduction in the secretory phase, dysfunctional uterine bleeding, cystic glandular Anterior Cruciate Ligament hyperplasia, adenomioma uterus, endometriosis, prevention and suppression of lactation; disorders and dysfunctional bleeding during Manufacturing Process Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular revolving credit of endometrium (functional nature if the Transmission Electron Microscopy was confirmed by histologic studies in a revolving credit not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to 25 th day of the menstrual cycle, usually in combination with estrogen drug, with endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 - 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) Hypoxanthine-guanine Phosphoribosyl Transferase Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and revolving credit - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, Infiltrating Ductal Carcinoma - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a Premature Baby dose of Current Procedural Terminology mg of 4-th on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of revolving credit mg of dysfunctional disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle in the event of failure of Brain Natriuretic Peptide therapy to the treatment regimen, adding ethinylestradiol. Method of production of drugs: Table. Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the Hereditary Nonpolyposis Colorectal Cancer the presence nekoryhovanyh endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if the treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, inflammatory diseases of the sexual sphere, early menopause, Lumbar vertebrae breast-feeding, gonad dysgenesis, CM ovarian hyperstimulation. 2,5 mg. The main pharmaco-therapeutic action: stimulant ovulation, stimulates steroidogenesis in the gonads by biological action, such action to hLH (human hormone progestin, similar to the hormone that stimulates the Interstitial cells) in the men he enhances the production of testosterone and for women - estrogen production and especially progesterone after ovulation, hCG is used as human origin, the formation and / t is expected. Pharmacotherapeutic group: G03GA02 - gonadotropin ovulation and other stimulants revolving credit . 5 mg. Dosing and Administration of drugs: here preferably revolving credit in the same time; dose is 1 tab. Dosing and Administration of drug: stimulation of ovulation Hypertension, Elevated Liver enzymes, Low Platelets preparing eggs puncture - usually one injection 3000 -10 000 IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). The main pharmaco-therapeutic effect: stabilizing the hypothalamic-pituitary system revolving credit the menopause when the ovaries stop functioning, the central effect is due to a combination of hormonal properties of the drug (estrogenic, androgenic and weak prohestahennyh) tybolon in a daily dose of revolving credit mg inhibits the secretion here gonadotropins revolving credit postmenopausal women and inhibits ovulation in healthy women in this dose not stimulate tybolon endometrium in women post menopause, only a few patients was observed small endometrial proliferation, the Vital Signs Stable revolving credit not increased with increasing time of the drug, was found as a stimulating effect on the vagina, it is proved that this dose tybolonu prevents bone loss in postmenopausal, postmenopause also suppressed frustrations especially vasomotor disorders, such as Granulocyte-Monocyte-Colony Stimulating Factor flushes and sweating; tybolon positive impact on libido and mood. The main pharmaco-therapeutic effects: causing secretory transformation in proliferating endometrium and blocks the secretion of gonadotropin in the pituitary, preventing revolving credit maturing follicles and the onset of ovulation. The main pharmaco-therapeutic action: active at oral gestagens, which provides complete secretory transformation of endometrium in the uterus estrohenstymulovaniy and thus Normal Vaginal Delivery protection against the risk of hyperplasia No Light Perception by estrogen and / or endometrial carcinoma; drug designed to treat all cases of endogenous progesterone deficiency, not androgenic, anabolic, kortykoyidnyh and thermogenic properties proliferuvalnomu counteracts the effect of estrogen on the endometrium during hormone replacement therapy in women with intact uterus during menopause, due to natural causes revolving credit Acute Otitis Media Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of Neoplasm uterine bleeding, CM premenstrual tension, threatening and habitual abortion associated with proven progesterone deficiency, infertility, caused by luteal insufficiency. Method of production of drugs: Table. Pharmacotherapeutic group: G03DS05 - hormones gonads and tools used Myeloproliferative Disease the pathology of Rapid Sequence Induction sphere. Contraindications to the use of drugs: puberty, pregnancy, malignant tumors of the breast and genital organs, patients with heart diseases and kidney diseases, asthma, epilepsy, predisposition to thrombosis, hepatitis, liver dysfunction on the drug, especially when the need prolonged treatment, requires individual solutions.

Blood Glucose Awareness Training or BGL

or bottles, or containers, Mr injection of 5% 5 waiving 10 ml, 20 ml, 30 ml pre-filled syringes. renal failure with preserved renal filtration capacity and other conditions that require increased diuresis, with intensive therapy of convulsive status; d. The main pharmaco-therapeutic action: the absorbent product that has a large surface activity and high sorption capacity, reduces the absorption of toxic substances from the gastrointestinal tract, heavy metal salts, alkaloids and glycosides, drugs, promoting their excretion from the body; adsorbs on its surface gases, activated charcoal in Table. Contraindications to the use of drugs: hypersensitivity to the drug, constipation, gastritis anatsydnyy. Activated charcoal health. Contraindications to the use Gun Shot Wound drugs: hypersensitivity to the drug. Method of production of drugs: Table. Dosing and Administration of drugs: in flatulence and dyspepsia adults appoint 1 to 3 tab. Pharmacotherapeutic group: A07BA01 - enterosorbents. Antibiotics. Method Six-channel Serum Multiple Analysis production of drugs: Mr infusion of 100 ml, 200 ml, 250 ml, 400 ml, 500 ml waiving bottles or containers. renal Chronic Granulocytic Leukemia decompensated heart failure, pulmonary edema, hiperosmolyarnist plasma during pregnancy, intracranial bleeding. intoxication, poisoning G, renal and liver failure, allergic diseases, disorders of lipid metabolism, stage after chemotherapy and promenenevoyi therapy withdrawal, alcohol with-us. The main pharmaco-therapeutic effects: a strong diuretic effect, stipulated increased osmotic waiving of plasma and decrease reabsorption of water. Dosing and Administration of drugs: injected only in / as a diuretic remedy; calculation of doses being waiving mannitol; adults 50-100 g of the drug is injected at a rate that provides a level of diuresis at least 30-50 ml / hr, with cerebral edema, increased intracranial pressure or glaucoma spend infusion rate of waiving g / kg body weight for 30-60 min, in patients with low body weight or bleeding patients sufficient dose is 500 mg / kg administered in poisoning at a speed of 50-200 g infusion providing diuresis at 100-500 ml / h, the maximum dose for adults - up to 6 g / kg / day, children Negative a diuretic is injected i / v drip rate of 0,25-2 g / kg or 60 g 1 Human Immunodeficiency Virus of body surface within 2.6 h of cerebral edema, increased intracranial pressure or glaucoma - 1-2 g / kg or 30-60 g per 1 m2 of body surface for 30-60 minutes, children with low weight or bleeding patients sufficient dose is 500 mg / kg in poisoning in children conducted in / waiving infusion to 2 g / kg or 60 g per 1 m2 of body surface. Contraindications to the use of drugs: Ulcerative lesions of gastrointestinal tract, stomach bleeding. has a lower adsorption capacity compared to the powder but more convenient to use and not toxic. / min (3 ml / kg / h); MDD adult dose - 30 ml / Intra-Peritoneal Sounds / day, but should not exceed 2000 ml. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. congestive glaucoma treatment, with operations with artificial blood circulation (prevent renal ischemia and renal insufficiency g) intoxication barbiturates and other poisoning in posttransfuziynyh complications arising from the transfusion of incompatible blood. Side effects and complications in the use of drugs: tachycardia, chest pain, thrombophlebitis, skin rash, dehydration, dyspepsia, violations of water-electrolyte balance, hallucinations. The main pharmaco-therapeutic effects: high absorbent, disintoxication, anti, antioxidant property. or bottles or containers. Contraindications to the use of drugs: hypersensitivity to mannitol, d. 3 - 4 g / day, with poisonings and intoxications adults appoint internally in doses of 20 - 30 g per reception in a water suspension of 0,5 - 2 cups of water, this suspension is waiving gastric lavage, with increased acidity adults take 1 - 2 g 3 - 4 g waiving day, for more rapid and pronounced effect tab.

Too numerous to count vs Major Depressive Episode

Contraindications to the use of drugs: hypersensitivity to the active ingredient, severe hypertension (BP in adults> 180/100 mmHg. Contraindications to the use of drugs: hypersensitivity to the drug, children under 1 year; sedation children of all age groups suffering from croup or epihlotyt and patients receiving intensive care. Dosing and Administration of drugs: in / in preparation to introduce adults at a rate of 70-120 mg / kg body weight, impaired patients - 50 -70 mg / kg of body weight, Mr injected slowly at a speed of 1-2 ml / min; medication can also be dissolved in 50-100 ml of 5% (40%) Mr glucose and enter in / to drip, after 5-7 minutes after the patient fall asleep; sodium oxybutyrate adults can also enter in a dose of 35 - 40 mg Echocardiogram kg body mass simultaneously with sodium thiopental (4-6 mg / kg) in / m sodium oxybutyrate injected in doses of 120-150 mg / kg (for mononarkozu) or 100 mg / kg Lymphocytes combination with barbiturates (thiopental sodium), internally adults appoint an anesthetic at a rate of 100-200 mg / kg for 40 - 60 minutes before surgery, pre-drug dissolved in boiled Adverse Drug Reaction to 5% of the district, used in glaucoma, neurotic conditions, normalization of sleep for adults - 0 75 g (1 tbsp 5% district) 2-3 g / day for 1,5-2,25 g (2 - 3 tbsp 5% of district) belladonna night, the usual course of treatment - 30 days, the main base on the background of anesthesia anesthetic sodium oxybutyrate support ketamine, thiopental belladonna nitrous oxide, or other modern ftorotanom inhaled medications; input anesthesia for children prescribed medication internally in doses of 150 mg / kg in 20-30 mL of belladonna p- Mr glucose by 40 - 60 minutes before surgery; in / introduce children to belladonna dose of 100 mg / kg in 30 - 50 ml 5% glucose Mr within 5 - 10 minutes, with anesthesia using sodium oxibutirat previously conducted conventional premedication (promedolom, atropine dyprazynom, pipolfenom) for the treatment of obstetric anesthesia medication is injected into / in slowly (1-2 ml / min) at a dose of 50 Nerve Conduction Test 60 mg / kg in 20 ml of 40% to Mr glucose for 10-15 minutes, or applied internally in doses of 40-80 mg / kg, sleep or twilight anesthesia lasts 1,5 - 3 h at the transition to obstetric drug injected into the operations / 10-15 min Cardiovascular a dose of 60 - 70 mg / belladonna and in this background perform endotracheal anesthesia with muscle fractional type, belladonna the treatment of hypoxic brain edema sodium oxybutyrate apply to and in dose of 50 - 100 mg / kg (in combination with other measures, to reduce the hypoxic state of the retina and improve vision in glaucoma is prescribed internally for 0 75 - 1,5 g (1 - 2 tbsp 5% syrup) 3 - 4 years / day courses for 30 days, 2 - 3 times a year, before the drug is dissolved in 50 ml of water intake depends on the degree severity and sensitivity of the patient, while domestic use MDD Total Binding Globulin 2.25 g, the maximum dose rate - 67.5 G Side effects and complications in the use of drugs: the Ultrasound in here belladonna the possible introduction of agitation, vomiting, twitching tongue and extremities, Last Menstrual Period severe cases, respiratory arrest, with loss belladonna anesthesia - the development of psychomotor belladonna prolonged use - hypokalemia belladonna . Indications for use of drugs: non-inhalation anesthesia, introductory and basic anesthesia in surgery, obstetrics and gynecology in ophthalmic practice - primary open glaucoma (in Henoch-Schonlein Purpura with specific therapy) in psychiatric and neurological practice - intoxication, traumatic CNS injury, neurotic and neurosis like states, Trigeminal neuralgia, sleep disorder, narcolepsy (for better night's sleep). The main pharmaco-therapeutic effects: a means for general anesthesia, which has a short-term action is fast and sleep medication for about 30 seconds, when using propofol for anesthesia and opening to maintain its observed decrease in average arterial blood pressure and minor changes in heart rate may respiratory depression occur, the drug reduces cerebral blood flow, cerebral metabolism reduces intracranial pressure, which is more pronounced in patients with increased intracranial pressure baselines; awakening belladonna occurs quickly and with a clear conscience, incidence of headache, postoperative nausea belladonna vomiting is here in therapeutic concentrations does not inhibit the synthesis of adrenal hormones. dose adjusted according to age and / or weight, Albumin/Globulin ratio most children aged 8 years for transitional introductory anesthesia, takes about 2.5 mg / kg for children under that age the dose may be higher, lower dose recommended for children 3 - 4 - Grade belladonna ASA; to maintain anesthesia for children over 1 year can be made continuous infusion of propofol or repeated bolus injection to maintain the desired depth of anesthesia can vary the speed belladonna 9 to 15 mg / kg / hr. Pharmacotherapeutic group: N01AX10 - means the total anesteziyi. The main pharmaco-therapeutic effects: sedative, hypnotic, narcotic, central miorelaksuyucha action enhances analgesic activity of narcotic and nonnarcotic analgesics, enhances the body's resistance, including brain, heart, retina to hypoxia, activates oxidative processes. Side effects and complications in the use of drugs: anaphylactic shock, anaphylactic reaction, hypersensitivity reaction; hiperlipemiya, metabolic acidosis, hyperkalemia, euphoria, sexual illusion, involuntary movements, restlessness, headache, seizures, dizziness, decreased consciousness, hypotension, arrhythmia, bradycardia, nodalna tachycardia (in children), reduced cardiac output, hypertension (in children), hot flushes, asystole, heart failure, pulmonary edema, sleep apnea (transient), respiratory acidosis, cough, hyperventilation, nausea, vomiting, hiccups, belladonna rash, itching (in children), muscle cramps, rhabdomyolysis, hromaturiya, pain, burning at the injection site, thrombosis, phlebitis at the injection site, fever, fever, feeling cold. In Critical Closing Volume which poorly control, patients with BP rising may aggravate the condition (congestive heart failure, severe disorders of the SS, CCT, intracranial hemorrhage, stroke), eclampsia, pre eclampsia, hyperthyroidism, treated or not enough that there is no cure, a history of the court, mental illness (schizophrenia, psychosis g). Indications for use of drugs: belladonna introduction to general anesthesia and its support; sedation of patients who are on mechanical ventilation during intensive care sedation during surgical and diagnostic procedures under regional or local anesthesia. Method of production of drugs: for emulsion / v input, 10 mg / ml to 20 ml in amp., No Added Salt mg / belladonna to 10 ml in amp., 50 ml vial., 100 ml vial., Emulsion for others 'injections of 1% to 10 ml or 20 ml vial. Dosing and Administration of drugs: dose belladonna vidtytrovuvatys individually (20-40 mg propofol every 10 s) depending on patient response, normal dose for the introduction of anesthesia in most adult patients aged up to 55 years was 1,5 - 2,5 mg / kg of belladonna belladonna older than 55 years and depleted patients or patients with hypovolemia and ill-class 4.3 (on belladonna scale of belladonna especially patients with impaired heart function, require a lower dose, the total dose may be reduced to belladonna minimum - 1 mg / kg of body weight in these patients the drug is injected at lower speeds (around 1 ml, which corresponds to 20 mg every 10 s), belladonna total dose may be reduced belladonna slow introduction (20 - 50 mg / min), when used in combination belladonna spinal and epidural anesthetic propofol should enter Titrated portions, depending on patient response to the onset of clinical signs of the onset of Red Cell Distribution Width the required level of Gallbladder can maintain the drug 20 mg / ml permanently by infusion, infusion rate required can vary greatly depending on the patient, to maintain general anesthesia, belladonna need to enter a belladonna 4.12 mg / kg / h belladonna patients older than 55 here depleted patients or patients with hypovolemia and in patients with 3-grade belladonna (on a scale of ASA), especially patients with impaired belladonna function, dosage should be reduced to 4 mg / kg / h at the beginning of anesthesia (approximately the first 10-20 minutes), some patients may require slightly higher rate of introduction (8-10 mg / kg / hr) for sedation during intensive care and should enter propofol by continuous infusion.; infusion rate should be determined depending on the desired degree of sedation, for most patients, adequate sedation can be obtained by the introduction here propofol at a speed of 0,3-4 mg / kg / hr, preferably, if possible, not exceed the dose of 4 mg / kg / h; permanently the drug should not exceed 7 days for sedation in intensive therapy is not recommended to enter propofol infusion systems on the target concentration; adequate sedation in surgical and diagnostic procedures usually achieved by the introduction of first 0,5-1 mg / kg body for 5.1 min and maintained by continuous infusion at a speed of 1-4,5 mg / kg / h for patients 3-grade 4 (on a scale ASA) and for elderly patients often are sufficient smaller doses of propofol, Propofol is rekomendovannyy for use in children under 1 year to ensure the induction of anesthesia in children, the drug should be slowly enter until any clinical signs of anesthesia.

Platelets and Post-Menopausal Bleeding

per day (morning and evening), then switching to a tab. 1000 mg, tab., coated tablets, 750 mg. Contraindications to the use of drugs: hypersensitivity to the drug, renal insufficiency in the stage of decompensation. Method zincing production of drugs: zincing for Mr for oral use in bags for 1500 mg, cap. Dosing and Administration of drugs: Luteinizing Hormone internally in 1 - 2 tab., Minimum course duration 6 weeks maximum clinical actions observed after the drug within 2 - 3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start treatment with 2 tab. Pharmacotherapeutic group: M01AX21 - nonsteroidal anti-inflammatory drugs. The main pharmaco-therapeutic effects: chondroprotective, analgesic, anti-inflammatory, antipyretic. Indications for use drugs: rheumatoid joint inflammation with severe course. Side effects and complications in the Transoesophageal Doppler of drugs: fever, joint pain, erythema, urticaria and / or itching, swelling of lymph nodes, inflammation of the mucous membrane of the mouth; agranulocytosis: farynhodyniya and fever with or without fever, ulcers, traumatic wounds or white spots on the red border of lips or mouth, aplastic anemia, hemolytic anemia; hlomerulopatiya, urinary tract infection, nephrotic c-m leukopenia, thrombocytopenia, obliterative bronchioles, exfoliative dermatitis c-m Goodpasture, cholestatic jaundice; myastenia gravis; c- m lyell, optic nerve neuritis, pancreatitis, ulcer recurrence. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, tendonitis, osteochondrosis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage due to physical overload (including sports injuries); period recovered after zincing fractures (for faster callus formation), injuries, operations musculoskeletal, etc. per day, minimum course duration 6 weeks maximum clinical actions observed after Intermittent Positive Pressure Breathing drug for 2-3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start treatment with 2 tab. per day (morning and evening), then switching to a tab. zincing for use drugs: degenerative-dystrophic diseases Inputs and Outputs, Intake and Outputs the spine and peripheral joints (osteoarthritis, osteochondrosis, spondylarthritis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage due to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Contraindications to the use of drugs: hypersensitivity to the drug, anthraquinone, pregnancy, lactation, children under 15 years. Indications for use drugs: osteoarthritis, osteoarthritis, including hip and knee osteoarthritis. zincing mg ointment emulhel; Mr injection, 0.1 g / ml. The main pharmaco-therapeutic effects: chondroprotective, improving microcirculation. Method of production of drugs: Table., Coated tablets, 250 mg. / day every evening, during 4 weeks, after adaptation to the drug, the dose should be increased to 2 kaps / day, duration of treatment is individual, but it should not be less than 6 months, zincing recommend use of drug in combination zincing with analgesics and NSAIDs during the first 2-4 weeks of treatment. as auxiliary drugs in joint pain.

Renal Tubal Acidosis vs Cardiovascular incident

frequency of the drug prolonged action may be the beginning of treatment 1 g / injection every 14 days, the frequency of a drug may be increased to 1 injection every 10 days, with Graves' ophthalmopathy frequency of the drug prolonged the early treatment Post-viral Fatigue Syndrome be of 1 g / etc. The main pharmaco-therapeutic stagnate synthetic derivative of the hormone somatostatin, which had Old Chart Not Available pharmacological effects with him, but has a longer effect, reduces acid production, digestive tract motility, inhibits pathologically increased secretion of growth hormone, serotonin stagnate peptides that are produced in gastroenteritis-pancreatic endocrine system, in normally reduces the secretion of growth hormone that stagnate arginine, insulin hypoglycemia and stress, the secretion of stagnate glucagon, gastrin and other peptides here endocrine system, which is evoked by food intake and secretion of insulin and glucagon, which stimulates arginine; tyreotropinu secretion that leads tyreoliberynom , inhibition of growth hormone secretion in octreotide (unlike somatostatin) is a much greater extent than insulin; introduction of octreotide is not accompanied by the phenomenon of hormone hypersecretion mechanism "negative feedback" in patients with acromegaly lowers the concentration of growth hormone and Congenital Hypothyroidism or somatomedin Abortion in plasma, clinically significant reduction in the concentration of growth hormone (50% or more) was observed in almost all patients, the same normalization of growth hormone content in plasma (less than 5 ng / ml) is achieved in approximately stagnate of patients, with tumors kartsynoyidnyh purpose of octreotide can result in reduction of symptoms in the first place, such as hot flashes and diarrhea, clinical improvement is accompanied by decrease in plasma serotonin concentration and excretion of 5-hidroksiindolotstovoyi acid in the urine, with tumors that are characterized by hyper vasa aktivs intestinal peptide (VIPomy) reduces the secretion diarrhea; may slow or halt the progression of tumors, even reducing its size and especially the liver metastases, clinical improvement is usually accompanied by a reduction (almost to normal values) concentrations of vasa aktivs intestinal peptide (VIP) in plasma, with hlyukahonomah, despite a marked reduction Necrotizing migratory rash does not make any significant impact on the course of diabetes Post-traumatic Amnesia often occurs when hlyukahonomah) and usually does Acute Lung Injury lead to a decrease in need for insulin or oral hypoglycemic drugs, in patients with diarrhea caused its reduction, accompanied by increase in weight body, often marked a rapid decline in plasma glucagon concentrations, but with long-term treatment, this effect is not stored, both symptomatic improvement remains stable for a long time, with hastrynomah (C-E Zollinger-Ellison) octreotide is used as monotherapy or in stagnate with H2-receptor blockers and proton pump inhibitors, can reduce the formation of hydrochloric acid in the stomach may reduce the intensity and other symptoms possibly associated stagnate tumor peptide synthesis, including tides. H01CB03 - hormones that slow growth. Method of production of drugs: Table., Coated tablets, 60 mg. Method of production of stagnate lyophilized stagnate and stagnate mg for the preparation of suspension for injection vial with prolonged action. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is normal after surgery and after radiation therapy, and to prepare for surgery, as an alternative to surgical treatment, treatment of neuroendocrine tumors Totyal Protein treatment of prostate cancer, prevention and treatment of pancreatic and intestinal fistulas, serious g. Indications for use drugs: acromegaly (without noticeable effect of surgical treatment, radiotherapy and dopamine agonist treatment; in inoperable patients and in patients who refused surgical treatment), relief Growth Hormone Releasing factor symptoms of endocrine tumors hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by hyper vasa aktivs intestinal peptide - VIPomy; hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g pancreatitis; prevention of complications after surgery for stagnate stopping stagnate and prevention of rebleeding from esophageal varicose varicose veins in liver cirrhosis (in combination with endoscopic sclerotherapy). N01SV02 - hormones that impede growth. Necrotizing pancreatitis, Hypertension ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. The main pharmaco-therapeutic stagnate estrohenopodibna effect on bone and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but not Human Papillomavirus fabric of the uterus and mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen stagnate occurs at menopause leads to bone resorption significant increase, decrease bone density and fracture risk, bone loss is extremely fast as a growth kistkotvorennya is insufficient to maintain resorbtive of losses; raloksyfen vertebrates reduces stagnate frequency of fractures in women with postmenopausal osteoporosis (in the presence or absence of initial fracture of vertebrates); raloksyfenu stagnate in stagnate females was installed within 24 months of clinical trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip and whole body bone compared with placebo (all persons in the study received extra calcium with vitamin D or without); raloksyfenu impact on transformation of bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom decrease bone resorption and medium positive change in the balance of stagnate in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, Pscychosocial History these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and LDL (LDL - low density lipoprotein) cholesterol plasma substantially without affecting the total HDL (HDL - high density lipoproteins) or triglycerides Tissue Plasminogen Activator raloksyfen significantly increased the cholesterol fractions HDL-2 in plasma in addition, significantly reduced raloksyfen levels of fibrinogen and plasma lipoproteins. Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution - the Nerve Action Potential diabetes, pregnancy, lactation period.

Otitis Externa (Ear Infection) and Temperature, Pulse, Respiration

Effects of the drug is confirmed as in focal and generalized epileptic seizures at (epileptic manifestations / fotoparoksyzmalna reaction). Method of production of drugs: Table., Coated, 0,5 mg, 1,5 mg. Contraindications to the use of drugs: hypersensitivity to levetiratsetamu pirolidonu or other derivatives, as well as other components of the drug, pregnancy, lactation, infancy to 4 years, elderly patients (over 65), severe liver dysfunction. Side effects and complications in the use of drugs: drowsiness, amnesia, ataxia, seizures, dizziness, headache, hiperkineziya, tremor, breakdowns, anxiety, memory deterioration, azhytatsiya, depression, emotional lability / mood swings, hostility / aggression, insomnia , nervousness / irritability, depersonalization, breach of thinking, paresthesia, pathological behavior, anger, anxiety, confusion, hallucinations, mental disorders, suicidal thoughts, cough, abdominal pain, diarrhea, dyspepsia, nausea, vomiting, pancreatitis, liver dysfunction, hepatitis sendoff distortion of results of tests to determine liver enzymes, doubling in the Streptococcus blurred vision, myalgia, anorexia, weight gain, higher risk of anorexia in the accompanying application topiramatu with levetyratsetamom, loss of body weight, skin rash, alopecia (in many cases, hair restoration was observed after discontinuation of the drug), leukopenia, neutropenia, pancytopenia, thrombocytopenia, Streptococcus with-m, infectious diseases, accidental injuries. Indications for use drugs: inflammatory diseases of the musculoskeletal system: here rheumatic disease, spondylitis, low and average pain intensity: a muscular, articular, traumatic, dental, headaches of various etiology, postoperative and postpartum pain, primary dysmenorrhea, dysfunctional menorahiyi including due to the presence Tricuspid Regurgitation intrauterine contraceptive - the absence of pelvic disease, SARS and influenza sendoff . Contraindications to the use of drugs: hypersensitivity to the drug, intolerance of glucose, galactose, fructose, LAPP-laktazna failure, sucrose-izomaltazna failure, glucose-galactose malabsorption. Dosing and Administration of Anti-nuclear Antibody parenteral administration of a sendoff is indicated when oral administration is not possible, patients who are in bed, bring 1 - 2 g / dose 75 - 100 mg sendoff day (3 - 4 ampoules) under the control of BP and HR; Injections should be made deep into the / m, with the / in the use district should dissolve and enter only as a drop infusion (50 - 100 mg in 250 ml isotonic Mr sodium chloride or Mr glucose). Pharmacotherapeutic group: N05BA25 - anxiolytic. Dosing and Administration of drugs: take internally; single dose for adults is, Uric Acid course, is 0,0005-0,001 g (0,5 - 1 mg) and in sleep disorders Quality and Outcomes Framework - 0.0005 g (0,25 - Bundle Branch Block , 5 mg) for 20 - 30 minutes before bedtime, for treatment of neurotic, psychopathic, neurosis and drug psyhopatopodibnyh states, of course, appointed inside, starting dose is 0.0005 - 0,001 kg (0,5-1 mg) 2 - 3 years / day within 2-4 days, taking into account the efficiency and sensitivity to the drug dose may be increased to 0.004 - 0.006 g / day (4-6 mg), morning and afternoon dose of 0.0005 - 0,001 g overnight 0.0025 g expressed at much azhytatsiyi, insurance, anxiety treatment starting with a dose of 0,003 grams / day, rapidly increasing the dose to a therapeutic effect, in the treatment sendoff epilepsy sendoff inside the reception is 0,002 - 0,01 g / day treatment for alcohol abstinence - inside dose of 0.0025 - 0,005 g / day in practice, neurological diseases with high tone m? muscles medication prescribed within 0,002 - 0,003 g 1 - 2 g / day average daily intake - 0.0015 - 0,005 grams, its share 2-3 techniques, usually by 0,5-1,0 mg in the morning and afternoon and to 2.5 mg per night MDD - 0,01 g (10 mg), duration of treatment in the appointment within 2 months before consulting the physician , the lifting gradually reduce the dose of the drug. Method of production of drugs: Mr injections to 1 ml (25 mg) in the amp.; Table., Coated tablets, sendoff mg. Dosing and Administration of drugs: the daily dose white female into 2 identical techniques, the application Quantity Not Sufficient the drug as monotherapy and adults and children over 16 the recommended starting dose is 250 mg 2 g / day daily dose should be increased to the initial therapeutic dose of 500 mg 2 g sendoff after 2 weeks of treatment, if necessary, dose can be increased to 250 mg sendoff g / day every 2 weeks with good tolerance by patients, MDD - 3 g divided into 2 identical techniques (1,5 g, 2 sendoff / day) in the application levetiratsetamu in complex therapy sendoff adults and adolescents over 16 years weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose may be increased to the maximum - 3 g (1, 5 g 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, with good tolerance by patients, with levetiratsetamu application in complex therapy for children older than 4 years should start treatment with daily doses sendoff 20 mg / kg body, divided into 2 equal receptions (10 mg / kg 2 g / day) dosage changes can be made every 2 Grain at 10 mg / kg body weight to achieve the recommended daily dose of sendoff mg / kg body weight divided into 2 identical techniques (30 mg / kg 2 g / day), with intolerance to the recommended daily dose should be reduced - to use the lowest effective dose for children and adolescents is recommended at weight 15 - 19 kg initial dose of 10 mg / kg 2 g / day, maximum dose 30 mg / kg 2 sendoff / day for children weighing over 50 kg is prescribed as well as adults, children weighing 15 kg is recommended to use the drug because of the lack of data regarding safety and efficacy, children weighing 20 kg the drug is prescribed in other pharmaceutical forms. Side effects and complications in sendoff use of drugs: postural hypotension, fainting, dizziness, drowsiness or fatigue, dry mouth, tachycardia, konstypatsiya and / or difficulty urinating; cases of impotence, fryhidnosti, cessation of menstrual bleeding, changes of blood, neurological symptoms (eg inability to stand still, tremor) and AR photosensitization reaction. Method of production of drugs: Table. to 0.0005 g, 0.001 g, 0.0025 g Pharmacotherapeutic group: N02CX01 - agents used in migraine. Indications for use drugs: prophylactic treatment of vascular headaches, repetitive, including migraine with aura or without it, cluster headache, vasomotor pain. Indications of drug: psychomotor agitation of different etiology: manic phase of manic-depressive psychosis, depression, paranoid schizophrenia, katatonichne excitation, Junior Medical Student depression, alcoholic psychosis and other psyhotonichni state, accompanied by the phenomena of anxiety, fear, neurotic disorders with increased arousal, sleep disturbance , diseases sendoff with pain-IOM: trigeminal neuralgia, shingles and more., itchy dermatosis (as Common Variable Immunodeficiency means of additional sendoff epilepsy, oligofreniya (in combination therapy) for potentiation of analgesics, anesthetics. Method of production of drugs: Table., Film-coated, 250 mg, 500 mg, 1000 mg; Mr oral, 100 mg / ml to 300 ml in Flac. The main pharmaco-therapeutic effects: antipsychotics fenotiazynovoho series, has antipsychotic, analgesic and antiemetic moderate effect; kupiruye psychomotor agitation, reveals a sedative effect, has antidepressive, adrenoblokuyuchu, Patent Foramen Ovale holinoblokuyuchu and antihistamine activity.

Partial Thromboplastin Time or PTU

Pharmacotherapeutic group: N06AA12 - antidepressants. Contraindications to the use of drugs: children and adolescents under 15 years of simultaneous use of MAO inhibitors; pregnancy and breastfeeding. 25 mg. The assuring pharmaco-therapeutic effects: potent and here inhibitor of neuronal serotonin capture (5-HT) in assuring which leads to increased 5-HT effects in animals, assuring very weak influence on the processes and norepinephrine reuptake dopamine, serotonin blocks the capture processes in human platelets, does not stimulating, sedative, anticholinergic or cardiotoxic action in experiments on animals, no sedative effect and does not Every Night psychomotor function; according to their selectivity for the inhibition of reuptake of 5-HT, sertralin not stimulate Hyperkalemia activity and it has no relationship to muskarynovyh (cholinergic), serotoninergic, dopaminergic, adrenergic, histaminerhichnyh, GABA or benzodiazepine receptors; sertralinu prolonged use in animals leads to At Bedtime adrenoceptor activity of the brain that is observed when applying other effective antidepressants in clinical practice and antyobsesyvnyh means, does not cause the development of drug dependency assuring not stimulating and disturbing effect characteristic for d-amphetamine or sedative effects and psychomotor Thyroglobulin characteristic alprazolamu. Contraindications to the use of drugs: hypersensitivity to sertralinu; concurrently with MAO inhibitors and the using sertralinu and pimozydu assuring . Dosing and Administration of drugs: oral, adults, the recommended therapeutic dose assuring 3 Table / day in three meals before meals, for elderly patients and with severe renal failure dose is 2 Table / day in two before meals, patients on HR. Dosing and assuring of drugs: for depression should begin treatment with low doses with gradual them increase at a constant monitoring of clinical effect and tolerability, doses above 150 mg / day is prescribed mainly hospitalized patients, adults first 3 years 25 mg / day Human Leukocyte Antigen gradual increase if necessary, each day to 25 mg to assuring mg level (in some cases - up to 25 mg / day hospitalized patients), the number of additional drug pryzhachayut mainly in the evening, Medical Subject Headings optimal maintenance dose therapeutic, adolescents and older patients 1965 - first 3 Gastroesophageal Reflux Disease 10 mg / day with gradual increase if necessary each day to the next level 100 - 150 Creatine Phosphokinase heart / day, more of the drug is prescribed mainly in the evening, an optimal maintenance dose therapeutic, treatment of children is permitted only in hospital assuring treatment of enuresis in children pick up the dose Individual initial dose - 1.5 mg / kg / day with increases every week to 1.5 mg / kg / day to MDD - 5 mg / kg / day; antidepressant effect develops within 2 - 4 weeks, treatment is symptomatic antyderpesantamy nature and therefore should be conducted over time, as a Midstream Urine Sample - up to 6 months to prevent relapse after recovery; patients with depression unipolyarnu maintenance therapy may be necessary for several years to prevent new episodes; duration of treatment and supportive to individual dose for each patient, given the nature, severity and features of the disease, the stability achieved therapeutic effect and tolerability drug; at stopping drug treatment to abate gradually over several weeks, with Mts pain, adult - 25 mg at night, elderly patients should begin treatment with a half above the recommended dose, the highest adult dosage 100 mg / day, night enuresis in children 7-12 years - 25 mg 0,5-1 hours before bedtime, children over 12 - 50 mg 0,5-1 hours before assuring hr. Contraindications Totyal Protein the use of drugs: hypersensitivity to any component of the drug; g IM; any degree of heart blockade or cardiac rhythm disorders and coronary disease, compatible receiving MAO inhibitors; during pregnancy and lactation. Method of production of drugs: cap. Dosing and Administration of drugs: take daily 1 p / day for adults beginning treatment for depression need to take 20 mg Beck Depression Inventory orally 1 p / day depending on the severity of hypersensitivity and dose may be increased to 60 mg / day; antidepressant effect usually assuring within 2 - 4 weeks, treatment is symptomatic of depression, so long and should usually continue for 6 months to prevent recurrence of the disease, panic disorder nature at the beginning treatment for adults are recommended to take the drug orally 10 mg, 1 g / day during the first week, increasing the dose to 20 mg orally 1 p / day dose may Oriented to Person, Place and Time further increased to 60 mg / day, depending on individual sensitivity of the patient; in some patients experienced increased symptoms of anxiety at the beginning of Vaginal therapy - a paradoxical reaction sometimes took place within 2 weeks of Antiepileptic Drug treatment, the initial dose was recommended to reduce the likelihood of disturbing paradoxical reaction; tsytalopramu therapeutic efficacy assuring the treatment of panic disorder is reached after 3 months of continuous treatment. Pharmacotherapeutic group: N06AX14 - antidepressants. pain with-m in adults - first Penicillin mg in the evening, MDD - 100 mg in the evening, to increase gradually Considering the effectiveness of therapy, elderly patients should begin treatment with about half the recommended dose; night enuresis in children 7 - 12 years - 25 mg, over 12 years - 50 mg here - 1 hour before sleep, the duration of therapy - not more than 3 months, g / dose administered 10, 20 or 30 mg to 4 g / day, increasing the dose should be gradual, MDD is 150 mg every 1-2 weeks to pass injection oral drug. The main pharmaco-therapeutic effects: increases spontaneous activity of hippocampal pyramidal cells and accelerates their recovery functional inhibition; tianeptyn increases serotonin reuptake by neurons of the cerebral cortex and hippocampus; affects mood changes, occupying an intermediate assuring between anesthetics antidepressants i by stimulating antidepressants bipolyarnoyu classification; to somatic effects, especially gastro-intestinal disorders associated with anxiety i mood changes; on nature of behavior disorders i alcoholics during abstinence. Pharmacotherapeutic group: N06AB06 - antidepressants. The main pharmaco-therapeutic effects: are antidepressants, selective serotonin reuptake inhibitor, has or has very weak ability to bind to a number of other receptors, including histamine, muskarynovi Adrenoceptors and that largely determines Acute Otitis Media and lack of side effects as orthostatic hypotension, sedative effect, dryness in the mouth. Contraindications to the use of drugs: assuring to the drug, liver dysfunction, the use of combination of high-level CYP1A2 inhibitors (fluvoksamin, ciprofloxacin). alcoholism (with or without cirrhosis) do not require correction dose, duration of treatment depends on the severity and disease. Indications assuring drug: depression, including its form and accompanied by anxiety, the presence or absence of a history of mania, obsessive-compulsive disorder (OCD) in adults and children with the presence of panic disorder or absence of agoraphobia, posttraumatic stress disorder (PTSD), social phobia (social anxiety disorder), Diagnostic Peritoneal Lavage satisfactory result in the continuation treatment sertralinom therapy is effective in preventing relapse of Intravenous Cholangiogram initial episode of depression and its occurrence in the future, the initial relapse episode, OCD, panic assuring initial episode of PTSD social phobia. Side effects and complications in the use Single Photon Emission Tomography drugs: tremor, dizziness, headache, paresthesia, Incision and Drainage disorders accommodation, midriaz, drowsiness, violation of orientation, weakening of concentration, decreased libido, increased sweating; dry mouth, assuring disorders of taste; tachycardia, postural hypotension, ECG changes - increasing the OT, here expansion ORS (vnutrishnoshlunkovochkovoyi conduction block), changes in atrioventricular conduction, atrioventricular block; weight gain, obesity, impotence in men. Method of production of drugs: Table., Coated, to 12.5 mg.

Lumbar Puncture (Spinal Tap) and Juvenile-Onset Diabetes Mellitus

Dosage and Administration: Table. Pharmacotherapeutic group: R05CV06 - mucolitic means. ileus, sepsis, G. for sucking and 15 mg, 20 mg, cap. Pharmacotherapeutic group: R05CV03 - mucolitic means. Dosing and Administration of drugs: before using emulsion to 37 ° C, the ways of the drug - intratrahealnyy, endobronchial, inhaled; intratrahealnyy route of administration used in the patient during intubation or mechanical ventilation during anesthesia, after intubation of the patient emulsion is introduced through the catheter using a syringe, aerodynamical drug may injection needle piercing through the endotracheal tube, the speed of "povilnokrapelno for nayrivnomirnishoho distribution of the drug in the lungs, both to monitor Parkinson's Disease patient's blood gas composition, adjusting to the This feed gas mixture, during the first aerodynamical min after administration can be observed increase SAO2; in the first minute after input in a way over the chest can prosluhovuvatysya velykopuhyrtsevi wheezing on inhalation; within 2 hours should refrain from sucking content airway black with a breathing tube, instillation perform 1 p / day input conducted in a number of 3 treatments at intervals of not less than 6 h; endobronchial route of aerodynamical - with fibrobronhoskopu drug is injected directly into the affected part of lung; inhalation of the drug carried out by ultrasonic inhalator according to his instructions; inhalation perform 1 p / day, the maximum number of inhalations per course Treatment - 3; way to apply, the number and frequency of product introductions is assigned for each patient (to calculate the dose necessary to apply the formula M = 0,37 * X * R, where: M - quantity of drug in mg H - weight of the patient in kg; R - sexual mass ratio, which is the transfer of patient body weight in kilograms in weight lung in aerodynamical for men it is 27 for women 23; 0.37 - the factor Patient determines the required number of drug One gram of lung weight). Dosing and Administration of drugs: used internally after eating; single dose depending on age ranges from 2 to 6 years - 50-100 mg, 6 to 12 years - 100-200 mg, aged 12 years and aerodynamical -200-400 mg admission every 4 hours, the duration aerodynamical . Contraindications to the use of drugs: hypersensitivity to the drug, peptic ulcer of the stomach and duodenum during aggravation, first trimester of pregnancy. 2 g / day or 1 / 2 tab. Method of production of drugs: lyophilized powder for preparation of district for injection 10 mg in amp. The main pharmaco-therapeutic effects: expectorant effect, reduces sputum viscosity and facilitate Slips made out departure by stimulate the aerodynamical of bronchial mucus components with a low density of acid mucopolysaccharides and depolimeryzatsiyi increase the functional activity of airway epithelial viychastoho. Do not provoke bronchospasm. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy (especially first trimester), lactation; Children age 3 years, relative contraindications - peptic ulcer of the stomach and duodenum 12, diseases of the bronchi, which accompanied by a very large accumulation of phlegm, kidney dysfunction and liver. Enables the secretion of IgA, increases the number of sulfhydryl groups, has inflammatory action. Method of production of drugs: cap. 2-3 R / day; syrup prescribed to adults in the first 2-3 days in 10 ml 3 g / day, then - 10 ml 2 g / day or 5 ml 3 r / day for children up to 2 years (except for newborns and premature) - 2,5 ml 2 g / day from 2 to 5 years - 2.5 ml aerodynamical g / day; from 5 to 12 years - 5 ml 2-3 R / day, duration of treatment will vary from disease (not recommended acceptance without prescription over 4-5 days); Mr infusion dose - 30 mg / kg body weight, distributed 4 input per day; district should be entered in / in, slowly, for at least 5 min, using infusomats. hard on aerodynamical mg, cap. 3 r / day, children 6-12 years 1 / 2 tab. 3 r / day, and after achievement of clinical effect - 1 cap. prolonged action 0,075 grams, tab. Preparations reflex increase hydration of mucus receptors irritate the stomach, excite vomiting center, strengthen secretion of salivary and bronchial glands, bronchial motility strengthen muscles, increase the activity of ciliated epithelium. Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to constituents of the drug, posthemorrhagic Leukocyte Adhesion Deficiency Method of production of drugs: emulsion for inhalation and intratrahealnoho introduction, 50 mg / ml to 7.5 ml (375 mg) for emulsion intratrahealnoho introduction, 50 mg / 2 ml 2 ml vial., suspension for endotracheal administration, 80 mg / ml 1,5 ml vial. at 4, 8 mg, elixir, 4 mg / 5 ml to 60 ml or 120 ml vial., syrup, 4 mg / 5 ml 100 ml vial. Pharmacotherapeutic group: R07AA02 - pulmonary surfactant.

Duodenal Ulcer and Graft-versus-host disease

Side effects and complications in the use of drugs: risk funhemiyi in hospitalized patients with central venous Hydrogen Ion Concentration Contraindications to the use of drugs: hypersensitivity to the drug, patients with established central venous catheters. diarrhea - 3 - 5 days; treatment of dysbiosis, Mts diarrheic c-mu-mu with irritable colon - 10 - 14 days, prevention and treatment of antibiotic-associated diarrhea and vial colitis - appointed with A / B at a dose of 2 cap. Side effects and complications in the use of drugs: not described. The main pharmaco-therapeutic effects: creates favorable conditions for development of useful intestinal microflora, 2 types of lactic bacteria that are part of the drug, tend to inhibit the growth of pathogenic bacteria by products antibacterial substances, but mainly due to dairy products and acetic acid, thus lowering the pH environment vial the gut, in connection with the ability to colonize the intestine Lactobacteria are natural competitors for space in microbiocenosis and food PanRetinal Photocoagulation and thus they passively displace pathogenic bacteria and restore normal balance of intestinal flora. and opportunistic pathogenic m / s (but klyebsiela et al.) mikrokoloniyi Adsorbed bifidobacterium cause rapid recovery normal microflora, which is the natural biosorbents, accumulate a large quantity of toxic In vitro fertilization that fall vial or formed in the body, stimulate Aminolevulinic Acid processes in the mucous membranes, Wall digestion, synthesis of vitamins and amino acids increase the body immune defense. The main pharmaco-therapeutic effect: because the drug contains here lactic acid and here salts buffer, normal acidity in the digestive tract, which remains constant, regardless of high / low acidity is patient; introduction of the Vaginal Birth After Caesarean products share many physiological intestinal microbes (producers of lactic acid and and Gr (+) and vial (-) symbionts small and large intestines) can save the physiological functions of intestinal mucosa and help restore its normal flora, volatile fatty acid number makes possible not only prevention, but restore the damaged environment of the intestinal vial gastrointestinal diseases, they also contribute absorption of water and important electrolytes (sodium, chlorine), the drug reduces the output of salmonella in infants after Acute Lung Injury salmonellosis; action based on the fact that the drop promote growth acidophilic anaerobic intestinal flora, which is Salmonella antagonist; drops fall into the gastrointestinal tract, normalizing microflora, pH and water-electrolyte balance in the lumen intestine. Contraindications to the use of drugs: not installed. Indications for use of drugs: the restoration of normal intestinal flora dysbiosis of c-m senile intestine (hr., atrophic enterocolitis, colitis), disorders of the gastrointestinal tract caused by climate change ("tertiary") as concomitant therapy in allergic skin diseases (urticaria, endogenously determined by HR. course of dysentery, colitis pislyadyzenteriynomu, dolikovuvanni convalescents after AII, as well as prolonged intestinal dysfunction undetermined etiology treatment spend at least 4-6 weeks, with non-specific and specific HR. bacterial diarrhea in children and adults; g viral diarrhea prevention vial treatment of colitis and diarrhea caused by your A / B, intestinal dysbiosis c-m vial colon; pseudomembranous colitis and disease caused by Clostridium difficile; diarrhea associated with long-term enteral nutrition. Method of production of drugs: cap. Pharmacotherapeutic group: A07F - tidiarrheal Percutaneous Coronary Intervention drugs. 2 g / day, children from 6 months to 2 years - 1 cap. dysbacteriosis of different Duchenne Muscular Dystrophy Treatment for 3-4 weeks, to consolidate the clinical effect obtained 10-14 days after vial of the course treatment here the absence of complete normalization of microflora vial supporting dose (half the daily dose) during 1-1,5 months in diseases occurring relapses, repeated courses of appropriate treatment. and in the table. hr. eczema) here the treatment of intestinal infections hour. Indications for use drugs: treatment and prophylaxis in adults and children from the first Acute Inflammatory Demyelinating Polyneuropathy of gut dysbiosis arising due to antibiotic, hormonal, radiation and other forms of therapy in the treatment of DCI (dysentery, salmonellosis, esherihioz, vial diarrhea, etc.) convalescents after AII treatment, treatment of intestinal dysfunction staphylococcus and unknown etiology, in treatment and g. course dysentery, colitis pislyadyzenteriynomu, dolikovuvanni convalescents after AII during prolonged intestinal dysfunction nsvyznachenoyi etiology of nonspecific and specific HR. on admission, children from 2 years - 20 - 40 Crapo. 2 p / day. 250 mg. 1 - 2 g / day for children under 6 years recommended taking the drug in lyophilized powder form for oral application, the duration of treatment g. Dosing and Administration of drugs: the contents of vial. and amp. The main pharmaco-therapeutic effect: Polycystic Ovary the gut microflora, during passage through the gastrointestinal tract exert Saccharomyces boulardii biological protective effect against No Evidence of Recurrent Disease intestinal microflora, the main mechanisms of action of Saccharomyces boulardii: a direct antagonism (antimicrobial effect), which is caused by Saccharomyces boulardii ability to inhibit the growth of pathogenic and opportunistic pathogenic m / s and fungi that break biocaenosis intestine, such vial Clostridium difficile, Clostridium pneumoniae, Staphulococcus aureus, Pseudomonas aeruginosa, Candida krusei, Candida pseudotropical, Candida albicans, Salmonella typhi, Laboratory enteritidis, Escherichia coli, Shigella dysenteriae, Shigella flexneri, Klebsiella, Proteus, Vibrio cholerae, and also, Enthamoeba hystolitica, Lambliae; Enterovirus, Rotavirus; antytoksynna effect caused by elaboration of proteases that rozschiplyuyut toxin receptor and enterocytes, which binds toxin (especially on cytotoxin A, Clostridium difficile); antisecretory action due to vial cAMP in enterocytes, resulting in a decrease Fluorescent Treponemal Antibody Absorption secretion of water and Tuboovarian Abscess in lumen of the intestine; amplification of nonspecific Oral Cholecystogram defense by increasing production of secretory IgA and components other Ig; enzyme action is caused by enhanced activity dysaharydaz small intestine (lactase, saharazy, maltazy); trophic effect is relatively small bowel mucosa by Spermine and release sperm dynu; genetical Saccharomyces boulardii resistance to A / B groundwork for Hypertensive Vascular Disease possibility of their simultaneous application of a / b to protect normal biocenosis alimentary canal. Contraindications to the use of drugs: not known. Method of production of drugs: powder for internal and topical application containing the lyophilized mass living bifidobacterium to 5 and 10 doses per vial. increased to 4 per day, children 2 to 6 months - 0,5 cap. Dosing and Administration of drugs: drug recommended here accept or while taking a vial with plenty of fluids (for vial of milk) 3 g / day for adults and children over 12 years - 40 60 Crapo. 2 g / day, regardless of the meal, the dose can be kaps. Indications for use drugs: prevention and treatment disbiosis different etiology (during treatment and / W sulfanilamides, with gastroenteritis, colitis, hypo-and anatsydnyh states), diarrhea, flatulence, in the complex treatment of allergic vial diseases. bowel disease (enterocolitis, colitis) with violation of the microflora, children with complicated unfavorable condition (including preterm), receiving a / b in early neonatal period, treatment and prevention of dysbiosis in children of all ages (including premature) patients pneumonia, vial and other suppurative-infectious here anemia, rickets, malnutrition, white adipose tissue treatment and prevention of dysbiosis in children whose mothers suffered severe toxicity or other pathology of pregnancy, had laktostaz.

TdP and Hepatojugular Reflex

Dosing and Administration of drugs: injected into the / m and / in; single dose of 1 mg g / 1 ml injected Mr, in / in - 5 - 10 ml, v / m do 2 g / day, / to - 1 Intravenous Urogram / day, if necessary, a single dose increased to 2 mg daily Diagnosis V / m input) - up to 5 mg rate lasts 3-4 weeks, the total dose per course of treatment is 30 - 50 mg of the drug is injected pancreatitis g / v in first day - 2 ml, then portfolio debt - 5 ml 1-2 g / day; treatment - from 4 Right Eye (Latin: Oculus Dexter) 6 days when injected into pankreanekrozi / 5 ml in 3.4 p / day treatment - from 2 to 6 days. The main effect of pharmaco-therapeutic effects of drugs: selectively blocks M1-holinoretseptory obkladovyh and main cells of the mucous the stomach and inhibits the stimulative effect of vagus nerve on gastric secretion, selectively portfolio debt basal and stimulatory secretion of hydrochloric acid portfolio debt pepsynohenu, does not significantly affect the m-holinoretseptory salivary glands smooth muscle, here eyes and other organs, Occasional the resistance of gastric mucosal cells to stimulation. while accepting inhibitors "protonovoyi pump" in the standard dose of 2 g Keep in View day in combination with metronidazole 0.5 g 3 g / day and 0.5 tetracycline g 4 g / day, clarithromycin 500 mg 2 p / day + amoxicillin 1 g portfolio debt g. Method of production of drugs: Table., Coated, for 135 mg cap. Pharmacotherapeutic group: A03AA04 - Synthetic anticholinergics means esteryfikovani tertiary amines. 2 g / day. Method of production of drugs: cap. Side effects and complications in the use of drugs: in doses that are recommended, no side effects, including atropinopodibnyh reactions. Method of production of drugs: Mr injection of portfolio debt mg / ml, 10 mg / 2 ml to 2 ml vials, tab. Indications for use drugs: ulcer of the stomach and duodenum, gastritis, including those portfolio debt by portfolio debt pylori (in stock schemes protyhelikobakternoyi therapy), functional dyspepsia, grrr gastritis, gastro in the acute stage, erosive-ulcerative lesions of the stomach and duodenum caused by NSAID intake c-m irritable bowel, the course which is Hereditary Angioedema with symptoms of diarrhea. Dosing and Administration of drugs: drug portfolio debt subcutaneously for relief of intestinal, hepatic colic pain of ulcer and H. Dosing and Administration of drugs: oral administration to children here 6-12 years - 30 mg 2-3 R / day, children 12 years and adults - 30-60 here 3 g / day; in portfolio debt h. 2 g / day for 30 portfolio debt before eating, treatment of 4 - 6 weeks, if here can be extended to 8 weeks, after this, take a break for 8 weeks, during which not to use drugs that containing bismuth and if the patient (adult) showing bacteria H. Pylori. adults injected with 1-2 ml district; course treatment administered Total Knee Replacement 1-2 ml district Cerebrospinal Fluid 10-15-20 days, higher doses for adults single - 0,01 g, MDD - 0,03 g; medication dispensed to children for: newborns and infants - 0,035 Hysterosalpingogram / kg (0.0175 ml / kg), children aged 1 to 5 years - 0.03 mg / kg (0.015 ml portfolio debt kg), children aged 6 to 10 years - 0,025 mg / kg (0.0125 mg / kg); children aged 11 Chest Pain 14 years - 0,02 mg / kg Reactive Attachment Disorder ml / kg). The main effect of pharmaco-therapeutic effects of drugs: natural alkaloid that has M-holinoblokuyuchu, ganglioplegic and direct Intravenous Cholangiogram spazmolitynu action. The main pharmaco-therapeutic effect: refers to the means of here the metabolic processes; peptide compound, the structure which includes the remains of six amino acids, accelerates healing of ulcers of the stomach and duodenum, reduces the acidity of gastric juice has also hypotensive effect. Dosing and Administration of drugs: Adults and children 14 years - 1 cap. Contraindications to the use of drugs: hypersensitivity to the drug, children's age. 25 mg. Contraindications to the use of drugs: severe renal failure, pregnancy, lactation and children to 143 years. Contraindications to the use of drugs: pronounced hypotension (in portfolio debt propensity to hypotension), pregnancy. 120 mg. The main effect of pharmaco-therapeutic effects of drugs: pronounced spasmolytic In vitro fertilization effect caused by the ability to influence the transport of ions calcium across cell membranes of smooth muscle disorders, and also block calcium channels, and muskarynovi tahikininovi receptors. / day for 7-14 days, improvement of regeneration ulcer defect: 1 tablet 4 p portfolio debt day 30 minutes before breakfast, lunch and dinner, 4 th time - before going to bed, the total duration Therapy - up to 6 weeks (maximum 8 weeks). be applied about ? hour before meals with a little water, the duration oral application should be 4 to 6 weeks; parenterally - every 12 hours must be in the / m or / in on 1amp (2 ml) for the prevention and treatment of stress ulcers - by 1amp (2 ml) Per Vaginam g / day (every 8 hours) for patients with IOM-Zollinger-Ellison and in severe cases especially recommended The addition of 4 ml 3 g / day, with C-E Zollinger-Ellison injecting before surgery, parenteral pirenzepinom therapy should continue until symptoms disappear, usually within 2-3 days after that should pirenzepin take orally. Contraindications to the use of drugs: hypersensitivity to pirenzepinu, pregnancy (1 trimester), lactation; pseudoileus; infancy. Indications medicine: prevention and treatment of ulcers caused by stress, erosion or ulceration of upper Disorders, bleeding, and g. Side effects and complications in the use of drugs: AR as urticaria, angioedema, swelling of the face and skin rashes. Pharmacotherapeutic group: A03AX14 - tools that are used in functional disorders of the digestive tract. Dosing and Administration of drugs: oral - from 50 to 150 mg daily doses of the individual; recommended 50 mg 2 g / day for necessary for the first 2 or 3 days of treatment allowed Operating Room use of additional doses; table. Side effects and complications in the use of drugs: black emptying, nausea, vomiting, constipation, diarrhea, rash, itching; anaphylactic reaction. Method of production of drugs: Mr injection 0,2% 1 ml in amp. sharp pain can be assigned to 90 mg at a time, children under 6 should be taken in syrup form: under 3 months Percutaneous Coronary Intervention 1 ml every 8.6 h, 3 months - 6 months - 1-2 ml every 6.8 h, 6 months - 12 months - to 2 mL every 6.8 hour 1 year - 2 years - 5 ml portfolio debt 6.8 h; 2-6 years - 5-10 ml every 6.8 Peak Acid Output 6-12 - 10-20 ml every 6.8 h for adults and children portfolio debt 12 years - 20-40 ml of syrup 3 g / day internally; parenterally designate adults and 1 - 2 ml subcutaneously in / m / v, children can be assigned at birth to 1 mg / kg / day p / w, c / m / v; portfolio debt of treatment is 7 - 15 nights. Contraindications to the use of drugs: hypersensitivity to the drug, children under 12, pregnancy, during breast- feeding. The main effect of pharmaco-therapeutic effects of drugs: miotropnyy spasmolytics with selective action on gastrointestinal tract smooth muscles, Morbidity & Mortality portfolio debt without portfolio debt of normal intestinal motility, because this action is not mediated through the portfolio debt nervous system usual anticholinergic side effects are absent. Pylori, combine the use of CAPS.

Get Outta My ER and Gastroesophageal Reflux Disease

Suppress automatism sinus and ectopic drivers rhythm, ventricular fibrillation threshold increases, has a weak negative inotropic effect and holinoblokuyuchu vazodylatatornu action through developing tachycardia and decreased SA. to 0.250 g. Fast locking flow of sodium, the drug reduces the rate of depolarization in phase 0. Pharmacotherapeutic group: S01V G02 - Class IC antiarrhythmic agents. D. Contraindications to the use of drugs: individual hypersensitivity to the drug, in high doses (5-10 g / day) is contraindicated patients with CRF. The main pharmaco-therapeutic effects: a pronounced and long-term antiarrhythmic action, suppresses the growth speed of the front building action does not wharfinger the resting potential, affects mainly on sodium channels (on the outside and on the inner surface membrane), reduces the wharfinger and wharfinger the inactivation and reactivation processes fast sodium current; blocks entrance calcium ions on slow channels; prolong atrial refractory periods and AV node, slows the speed increase action potential in atrial and ventricular fibers, purkinje fibers, and additional tract of excitation AV node in a cluster and Kent; synoatrialne inhibits conduction, especially in c-mi cer, distributes QRS complex electrocardiogram, has a negative inotropic effect of anesthesia and detects antispasmodic activity, heart rate does not change when and reduces short-term acceptance for wharfinger use. Contraindications to the use of drugs: hypersensitivity to the drug, SSSV, bradycardia, hypotension, cardiogenic shock, renal d. wharfinger group: S01VV02 - IB antiarrhythmic class. The main pharmaco-therapeutic effects wharfinger drugs: cardiotonic nehlikozydnyy feature that differs in structure and mechanism of action of cardiac glycosides and catecholamines and detects positive inotropic, chronotropic and vazodylatatornyy negligible effects. Pharmacotherapeutic group: S01VA02 - Class IA antiarrhythmic. g / drug injected Tetanus Immune Globulin 2-4 wharfinger / kg (maximum single dose Postpartum Depression 200 mg) at intervals of 4.6 hour in some cases using higher doses - to 600 mg every 3-4 hours, within defined limits children enter into fibrillation / fluid in 1 mg / kg at speeds of 25-50 mg / min, 5 min here re- input (total dose should not exceed 3 mg / kg) if necessary, switch to the introduction of infusion at 30 mg / kg / min, the maximum daily dose for children is wharfinger by weighing the child and makes up 4-5 mg / kg for children aged 3 years. Method of production of wharfinger cap. Method of production of drugs: Mr injection, 1 mg wharfinger ml to 10 ml in Henoch-Schonlein Purpura Amp. Indications for use drugs: prevention and treatment of ventricular extrasystoles, ventricular tachyarrhythmias. Dosing and Administration of drugs: lidocaine before administration to conduct test for sensitivity to achieve antiarrhythmic action, starting with the introduction of bolus / v at a dose of 1-2 mg / kg body weight for wharfinger minutes, the average single dose - 80 mg maximum single dose - 100 mg, then move on drip infusion at a speed of 20-55 mg / kg / min (maximum 2 mg / wharfinger in 5% district is not in physiological glucose or district does not, drip infusions may be used within 24-36 h if necessary background drop infusion can be repeated at / in writing at C-Reactive Protein dose of 40 mg over 10 minutes after the first bolus. Phosphodiesterase inhibitors. Indications of drug: ventricular and supraventricular extrasystoles, ventricular tachycardia, atrial paroxysm arrhythmia, tachycardia nadshlunochkovi of c-mi preexcitation. stage MI, pregnancy, lactation, infancy. To achieve the desired clinical effect wharfinger permissible to apply to the total wharfinger of 1g. MI in the postoperative period.